An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

AFP becomes one of the main source for international news. We've got various news from around the world. I can say that AFP news content is diverse and credible, and they can fit with the ...